Entyvio Shortage Update: What Patients Need to Know in 2026

Entyvio Shortage Update: What Patients Need to Know in 2026

If you rely on Entyvio (Vedolizumab) to manage your ulcerative colitis or Crohn's disease, keeping up with supply and access information isn't optional — it's essential. A missed dose can trigger a flare, and the stress of not knowing if your medication will be available adds an unwelcome layer to an already challenging condition.

This is your 2026 update on the Entyvio supply situation — covering what's happening with availability, why access can still be difficult, what the medication costs now, and what options are available if you're struggling to get your prescription filled.

Is Entyvio Still in Shortage?

As of March 2026, Entyvio is not formally listed on the FDA's drug shortage database. That means the FDA has not declared an official nationwide shortage of Vedolizumab.

However, that doesn't tell the full story. Many patients continue to report difficulty finding Entyvio in stock at specialty pharmacies and infusion centers. The gap between "no official shortage" and "I can't get my medication" is real, and it's driven by several factors that we'll cover below.

For context, Entyvio is a specialty biologic manufactured solely by Takeda Pharmaceuticals. It generated approximately $6.4 billion in worldwide sales in 2025, reflecting enormous global demand. When demand is this high and supply comes from a single source, even minor disruptions can create access challenges for individual patients.

Why Is Entyvio Still Hard to Find?

Several factors contribute to ongoing access challenges:

Single Manufacturer, No Biosimilar

Takeda is the only company making Entyvio. Unlike Humira (Adalimumab), which now has multiple biosimilars on the market driving competition and supply, Entyvio has no approved biosimilar as of 2026. Companies like Alvotech are developing biosimilar candidates, but these aren't expected to launch until 2028 at the earliest.

Specialty Distribution Channels

Entyvio isn't stocked at regular retail pharmacies. It flows through specialty pharmacy networks and infusion centers — a much narrower pipeline than standard medications. Any bottleneck in this distribution chain can leave patients without access.

Complex Biologic Manufacturing

As a monoclonal antibody, Entyvio requires sophisticated manufacturing processes that take months from start to finish. Scaling up production isn't as simple as running an extra shift at a factory. Raw material shortages, quality control requirements, and regulatory oversight all add time and complexity.

Prior Authorization and Insurance Barriers

Even when Entyvio is physically available, insurance hurdles can create the experience of a "shortage." Prior authorization requirements, step therapy mandates, and formulary restrictions can delay access by days or weeks.

For more on these challenges, read our detailed guide on why Entyvio is so hard to find.

What Does Entyvio Cost in 2026?

Entyvio remains one of the most expensive IBD medications on the market:

• IV Infusion (300 mg vial): Approximately $9,882 per dose with a coupon (cash price)
• Entyvio Pen (108 mg SC): Approximately $3,500 per pen with a coupon
• Annual cost estimate: $40,000 to $80,000+ depending on formulation and dosing schedule

For patients on the IV formulation receiving infusions every 8 weeks (approximately 6-8 times per year after the first year), annual costs can exceed $60,000. The subcutaneous pen, given every 2 weeks, adds up even faster.

The good news is that most patients don't pay these full amounts. Insurance, manufacturer programs, and patient assistance can dramatically reduce out-of-pocket costs. For a complete breakdown, see our guide on how to save money on Entyvio.

New Options and Developments in 2026

Subcutaneous Entyvio Pen

The Entyvio Pen (subcutaneous formulation) is now approved for maintenance therapy in both ulcerative colitis and Crohn's disease. This is a significant development for patients who prefer the convenience of at-home self-injection over visiting an infusion center every 8 weeks.

If you've been receiving IV Entyvio and are interested in switching to the pen, talk to your gastroenterologist. After completing your IV induction doses, you may be eligible to transition to the at-home SC formulation.

Biosimilar Pipeline

Several companies are working on Entyvio biosimilars:

• Alvotech (AVT16/AVT80): Reported positive Phase 3 pharmacokinetic results in early 2026
• Polpharma: Also in Phase 3 development

These biosimilars could bring competition to the market by 2028-2032, potentially lowering costs and improving supply. But for now, brand-name Entyvio remains the only option.

How to Find Entyvio in Stock

If you're having trouble finding Entyvio, here are your best options:

1. Use Medfinder to search for specialty pharmacies and infusion centers with Entyvio in stock near you.
2. Contact EntyvioConnect at 1-844-368-9846 for help locating your medication and coordinating care.
3. Ask your GI doctor to check with alternative specialty pharmacies or infusion centers.
4. Consider both formulations — if IV infusion appointments aren't available, ask about the SC pen, or vice versa.
5. Plan ahead — start the refill or scheduling process at least 2 weeks before your next dose is due.

For a complete walkthrough, read our guide on how to find Entyvio in stock near you.

Final Thoughts

The Entyvio supply situation in 2026 is nuanced. There's no official FDA shortage, but real-world access challenges persist for many patients. High demand, a single manufacturer, specialty distribution, and insurance barriers all contribute to the difficulty.

Stay proactive: use Medfinder to monitor availability, work closely with your GI team, and explore all the financial assistance options available to you. Your treatment doesn't have to be interrupted.

More resources:

• Alternatives to Entyvio
• Entyvio Side Effects: What to Expect
• How to Find a Doctor Who Can Prescribe Entyvio
• What Is Entyvio? Uses, Dosage, and More